Abstract
More research and new treatment options are needed in all stages of lung cancer. To this end immunotherapy needs a revival in view of recent improved technologies and greater understanding of the underlying biology. In this review we discuss mechanisms of tumour immunotherapy, non-specific, specific and adoptive, with particular reference to a direct therapeutic action on all subtypes of lung cancer.
Article PDF
Rights and permissions
About this article
Cite this article
Al-Moundhri, M., O'Brien, M. & Souberbielle, B. Immunotherapy in lung cancer. Br J Cancer 78, 282–288 (1998). https://doi.org/10.1038/bjc.1998.486
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.486
This article is cited by
-
Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications
Cancer Chemotherapy and Pharmacology (2018)
-
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Journal for ImmunoTherapy of Cancer (2016)
-
Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
Clinical Pharmacology & Therapeutics (2014)
-
Activation of innate immunity to reduce lung metastases in breast cancer
Cancer Immunology, Immunotherapy (2010)